TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02319161
Drug: Calcium channel blocker and beta blocker
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
Study: NCT00519376
Drug: GW642444M
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT00519376
Drug: GW642444H
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT00519376
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03729258
Drug: Infex 400 MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infex (cefpodoxime) 400mg once a day (QD) for 10 days
Study: NCT03729258
Drug: Infex 200 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
Study: NCT02321293
Drug: Tyrosine Kinase Inhibitor gefitinib (Iressa)
Normalized name: gefitinib Oral Tablet [Iressa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg PO daily until progression
Study: NCT04301479
Drug: hydrocortisone sodium succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
Study: NCT02321293
Drug: Tyrosine Kinase Inhibitor erlotinib (Tarceva)
Normalized name: erlotinib Oral Tablet [Tarceva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg PO daily until progression
Study: NCT03305419
Drug: GSK2982772 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
Study: NCT03305419
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
Study: NCT00834990
Drug: Depakote®
Approvals — FDA: no, EMA: no, PMDA: no
Description: delayed-release 500 mg tablet
Study: NCT00988364
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20mg daily for 3 months.
Study: NCT00988364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet daily times 3 months.
Study: NCT03295383
Drug: Cyclophosphamide 50Mg Oral Tablet
Normalized name: Cyclophosphamide 50mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally.
Study: NCT03295383
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide placebo will be administered orally once daily
Study: NCT01235923
Drug: three times weekly Epo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
Study: NCT00521599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02609230
Drug: ONC-201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02312804
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGJ398 will be administered orally once daily on each day of the 21 day cycle.
Study: NCT03585036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
Study: NCT02604654
Drug: Yiqitongluo granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered after dissolved
Study: NCT00004495
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004495
Drug: pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03061721
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
Study: NCT03447314
Drug: GSK1795091
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1795091 will be available as solution for injection
Study: NCT03447314
Drug: GSK3174998
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
Study: NCT03447314
Drug: GSK3359609
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3359609 will be available as solution for infusion.
Study: NCT01083979
Drug: Liposomes
Normalized name: liposomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation
Study: NCT02082457
Drug: YKP10811 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02082457
Drug: YKP10811 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02082457
Drug: YKP10811 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00434083
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01168791
Drug: doxorubicin in combination with palifosfamide-tris
Approvals — FDA: no, EMA: no, PMDA: no
Description: palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles.
Study: NCT01168791
Drug: doxorubicin in combination with placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles.
Study: NCT00309699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 3 weeks
Study: NCT04319380
Drug: SMC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
Study: NCT01713283
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study: NCT00812006
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
Study: NCT00937144
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02130713
Drug: Third generation fluoroquinolone
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg
Study: NCT01571050
Drug: Fresh MFP/CaCO3 toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
Study: NCT01571050
Drug: Fresh NaF/SiO2 toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
Study: NCT01571050
Drug: Aged NaF/SiO2 toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
Study: NCT01571050
Drug: Aged MFP/CaCO3 toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
Study: NCT01939002
Drug: BIIB017
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01939002
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01133405
Drug: LY2886721
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT01133405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT02629848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib placebo-matching tablets
Study: NCT00433160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily, subcutaneous
Study: NCT00075725
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00075725
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00075725
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00075725
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00075725
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT02499900
Drug: Copaxone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injections
Study: NCT03222973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00395135
Drug: Matching Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
Study: NCT03073018
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration, capsules
Study: NCT03073018
Drug: Pravastatin Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, capsules
Study: NCT00492479
Drug: Kinerase Pro+Therapy Line day repair, serum, night repair
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00492479
Drug: Kinerase Pro+Therapy Line Ultra rich day repair
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01438801
Drug: Nutropin [Somatropin (rDNA origin) for injection]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
Study: NCT01792375
Drug: 10mg Dinoprostone vaginal insert
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening
Study: NCT04627675
Drug: CORVax
Normalized name: SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-encodable coronaviral vaccine
Study: NCT04627675
Drug: IL-12 plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: cytokine
Study: NCT03224403
Drug: Test acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 2 Test acetaminophen 500 mg tablets
Study: NCT03224403
Drug: Commercial acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 2 acetaminophen 500 mg caplets
Study: NCT03224403
Drug: Commercial ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
Study: NCT03224403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo caplets
Study: NCT03165123
Drug: Oral Azithromycin tablet
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin tablet will be given one hour before induction of anaesthesia.
Study: NCT06461598
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
Study: NCT03511625
Drug: Acthar Injectable Product
Normalized name: Acthar Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acthar is a non-specific melanocortin receptor agonist
Study: NCT03304054
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets matching amifampridine phosphate, 3 to 4 times a day
Study: NCT02727387
Drug: TEMIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Window therapy frontline for VHR patients
Study: NCT02727387
Drug: CYC
Normalized name: Cycrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
Study: NCT02727387
Drug: BUMEL
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation phase
Study: NCT02727387
Drug: VIN
Normalized name: Ravin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
Study: NCT02968160
Drug: Telmisartan 40mg + Rosuvastatin 20mg
Normalized name: telmisartan 40 MG
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02968160
Drug: Telmisartan 80mg + Rosuvastatin 20mg
Normalized name: telmisartan 80 MG
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02968160
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02791191
Drug: LY3202626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02791191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03985982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
Study: NCT00230802
Drug: Anticipatory dose increase of levothyroxine
Normalized name: combinations of levothyroxine and liothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
Study: NCT00230802
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
Study: NCT00230802
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will increase levothyroxine by 3 extra tablets of their current dose per week.
Study: NCT03165240
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT03165240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01428037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet vaginal inserted at 4 hrly interval with maximum of three doses
Study: NCT00258232
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00258232
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01981863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in same volume as in experimental arm.
Study: NCT00004248
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00731653
Drug: Combination Product: BCI-024 + BCI-049
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCI-024 and BCI-049 once a day at bedtime for 6 weeks
Study: NCT00000273
Drug: opiates
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescription opioids
Study: NCT03012100
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00269269
Drug: antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03788018
Drug: saline IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Study: NCT04051710
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Study: NCT04051710
Drug: Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Study: NCT04051710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Product
Study: NCT01791881
Drug: Hugeltox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
Study: NCT00801034
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 1 tablet 2 times per day in 28 days
Study: NCT02926326
Drug: BCT197
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of BCT197
Study: NCT02926326
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 daily doses of Azithromycin
Study: NCT00309712
Drug: simvastatin 20 mg and placebo
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00309712
Drug: fenofibrate 160 mg and simvastatin 20 mg
Normalized name: simvastatin and fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04092894
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral placebo (same non-identifiable form as active comparator)
Study: NCT02284529
Drug: Orectalip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
Study: NCT01832129
Drug: Oral administration of vitamin B12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
Study: NCT01832129
Drug: i.m. injection of vitamin B12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
Study: NCT03389555
Drug: vitamin C, vitamin B1, hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
Study: NCT03389555
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study: NCT03806556
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV medication administered after patient meets inclusion/exclusion criteria
Study: NCT03224507
Drug: KRdD followed by auto-HCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
Study: NCT03224507
Drug: KRdD only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
Study: NCT00685269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00406874
Drug: omega 3 fats
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg daily
Study: NCT00406874
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 micrograms daily
Study: NCT05027126
Drug: Fixed dose Dexketoprofen-Vitamin B Complex
Normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
Study: NCT01522521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (i.v.)/year + daily calcium and vitamin D for 2 years
Study: NCT01424891
Drug: Simvastatin 80 mg
Normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with 80 mg of simvastatin over a period of 8 weeks
Study: NCT01424891
Drug: Sim10/Eze10
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
Study: NCT01424891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with placebo over 8 weeks
Study: NCT00347438
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
Study: NCT00949754
Drug: honeybee venom (Apitoxin (Korea) Apitox (USA))
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple intradermal injections of 100 ug pure honeybee venom
Study: NCT03334851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.